Avelumab (trade name Bavencio) is a fully human monoclonal antibody developed by Merck KGaA and Pfizer and Eli Lilly and Company in Canada as a pharmaceutical drug for use in immunotherapy, originally for the treatment of non-small-cell lung carcinoma (NSCLC)... Wikipedia

 

Manufacturer's Website: Bavencio

 

Average retail cost: $3,200/month

Pembrolizumab (formerly MK-3475 and lambrolizumab, trade name Keytruda) is a humanized antibody used in cancer immunotherapy. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells... Wikipedia

 

Manufacturer's Website: Keytruda

 

Average retail cost: $7,000/vial

Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). In 2015, it was in clinical trials as an immunotherapy for several types of solid tumors. It was under investigation by Genentech/Roche. In April 2016 Roche announced that atezolizumab had been granted fast track status for lung cancer by the FDA... Wikipedia

 

Manufacturer's Website: Tecentriq

 

Average retail cost: $9,400/vial

Durvalumab is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules. Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum- containing chemotherapy.... Wikipedia

 

Manufacturer's Website: Imfinzi

 

Average retail cost: $15,000/month

Nivolumab, marketed as Opdivo, is a medication used to treat cancer. It is used as a first line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF, as a second-line treatment following treatment with ipilimumab and if the cancer has a mutation in BRAF, with a BRAF inhibitor, as a second-line treatment for squamous non-small cell lung cancer, and as a second-line treatment for renal cell carcinoma... Wikipedia

 

Manufacturer's Website: Opdivo

 

Average retail cost: $31,630/month